Camrelizumab: all 354 studies that test it
Page 4 of 4. Open to participants first (126), then studies with results posted, then the rest; newest registration first within each.
- Camrelizumab Combined With Apatinib for Recurrent Resistant GTNCompletedNCT04047017Phase 2
- Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced OsteosarcomaWithdrawnNCT04044378Phase 1/2
- Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver TransplantStatus unknownNCT04035876Phase 1/2
- SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular CarcinomaStatus unknownNCT04014101Phase 2
- Apatinib Plus SHR1210 in Advanced Mucosal MelanomaStatus unknownNCT03986515Phase 2
- PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral MelanomaStatus unknownNCT03955354Phase 2
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBCCompletedNCT03945604Phase 1
- The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCCStatus unknownNCT03917966Phase 2
- Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal CancerStatus unknownNCT03912857Phase 2
- A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid TumorsTerminatedNCT03871855Phase 1
- Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical ResectionStatus unknownNCT03839550Phase 2
- Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsStatus unknownNCT03827837Phase 2
- A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCCStatus unknownNCT03817658Phase 2
- SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical CancerCompletedNCT03816553Phase 2
- A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic TherapyCompletedNCT03813784Phase 3
- FUSCC Refractory TNBC Umbrella (FUTURE)Status unknownNCT03805399Phase 1/2
- A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCCStatus unknownNCT03793725Phase 2
- Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung CancerTerminatedNCT03777124Phase 2
- Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03766178Phase 2
- PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.CompletedNCT03755440Phase 2
- SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung CancerStatus unknownNCT03755115Phase 2
- SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After SurgeryStatus unknownNCT03722875Not applicable
- Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT03707509Phase 3
- PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell LymphomaStatus unknownNCT03701022Phase 2
- Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal CancerCompletedNCT03691090Phase 3
- Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCCStatus unknownNCT03671265Not applicable
- A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCStatus unknownNCT03668496Phase 3
- A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLCTerminatedNCT03666728Phase 2
- SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal CancerTerminatedNCT03645876Phase 2
- Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach AdenocarcinomaStatus unknownNCT03631615Phase 2
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.Status unknownNCT03605706Phase 3
- A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCCStatus unknownNCT03601598Phase 1/2
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLCStatus unknownNCT03557411Phase 2
- Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLCStatus unknownNCT03527251Phase 1
- Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid TumorsStatus unknownNCT03491631Phase 1
- SHR-1210 in Combination With GEMOX in Patients With Advanced BTCCompletedNCT03486678Phase 2
- PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT03427827Phase 3
- A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBCCompletedNCT03394287Phase 2
- A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild TumorStatus unknownNCT03393416Phase 1
- SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell LymphomaStatus unknownNCT03363555Phase 2
- Apatinib Plus Anti-PD1 Therapy for Advanced OsteosarcomaCompletedNCT03359018Phase 2
- Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLsStatus unknownNCT03346642Phase 1/2
- Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCCCompletedNCT03222440Not applicable
- Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal CancerCompletedNCT03187314Phase 2
- The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid TumorsTerminatedNCT03182673Phase 1
- Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid TumorsStatus unknownNCT03171220Phase 1/2
- A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLCCompletedNCT03134872Phase 3
- A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC SubjectsCompletedNCT03121716Phase 1
- A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCStatus unknownNCT03085069Phase 2
- Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric CancerStatus unknownNCT02942329Phase 1/2
- A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor SubjectsCompletedNCT02742935Phase 1
- A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced MelanomaCompletedNCT02738489Phase 1
- A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor SubjectsCompletedNCT02721589Phase 1
- A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer PatientsCompletedNCT02492789Phase 1